Common Stock SEC Reporting - Current
OTC Pink Current Information
Contact Info
  • 442 Littlefield Avenue
  • South San Francisco, CA 94080

Business Description

Update Company Profile
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Not Available
Latest Report Jun 30, 2016 10-Q
CIK 0001293310
Fiscal Year End 12/31
OTC Marketplace OTC Pink Current
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2000
Employees Not Available
Company Officers/Contacts
Cameron Durrant CEO
David Tousley Interim CFO
Morgan Lam CSO
Company Directors
Cameron Durrant Chairman
Ronald Barliant
Dale Chappell
Ezra M. Friedberg
Timothy Morris
Company Notes
  • Note = On December 29, 2015, KaloBios Pharmaceuticals, Inc. filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware(Case No. 15-12628).
Service Providers
Accounting/Auditing Firm
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
KBIO Security Details
Share Structure
Market Value1 $47,987,731 a/o Oct 27, 2016
Authorized Shares Not Available
Outstanding Shares 14,903,022 a/o Sep 22, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Transfer Agent(s)
Shareholders of Record 47 a/o Sep 01, 2016
Short Selling Data
Short Interest 2,658 (0%)
Sep 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security